Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Fig. 2

Imaging and Histological analysis from Case 2 patient: (a) MIP image (PET-CT scan) performed before the beginning of IO showing an multiple areas of pathological uptake localized at mediastinum, pectoral, axillary, gastric, mesenteric and iliac region (SUV max = 7.7); (b) MIP image (PET-CT scan) performed after the first course of IO showing a reduction of almost all the previously detected lesions, considered a Partial Metabolic Response (Deauville IV); (c) MIP image (PET-CT scan) performed after the second and last IO course showing the resolution of all the previously described lesions, with the persistence of slight pathological uptake next to the gastric great curvature and the hepatic hilus (SUV max = 4, Deauville IV); (d) Histological image from a duodenal biopsy documenting the epithelial surface of intestinal villa and submucosa diffusely infiltrated by blasts cell (Light Microscopy, H&E); (e) Histological image from a Duodenal biopsy showing the duodenal surface with the brush border on the epithelium and the submucosal populations of B-ALL neoplastic cells (Light Microscopy, Wright-Giemsa); (f) Histological image from a Duodenal biopsy with specific immunostaining showing CD22-positive B-ALL blasts (Light Microscopy)

Back to article page